J Drugs Dermatol. 2025 Dec 1;24(12):1195-1202. doi: 10.36849/JDD.9517.
ABSTRACT
BACKGROUND: Cutaneous hyperpigmentation, which includes melasma, post-inflammatory hyperpigmentation, and solar lentigines, significantly impacts patients’ quality of life. The overproduction of melanin is mediated by activation of the skin enzyme tyrosinase, leading to excess melanin deposition in the skin. Thiamidol (isobutylamido thiazolyl resorcinol) formulations have been previously shown to be effective in reducing the cutaneous pigmentation associated with this human skin enzyme.
METHODS: A randomized study was performed with 90 subjects clinically presenting with facial hyperpigmentation (Thiamidol serum n=43; Thiamidol regimen n=47) as measured by colorimeter and individual typology angle (ITA0) to assess the efficacy of a Thiamidol-based serum (2X daily application; morning/night) or a Thiamidol-based regimen (day lotion with SPF 30 + serum in morning; night cream + serum at night) for 12 weeks with a 6-week regression period.
RESULTS: A significant visible reduction in facial hyperpigmentation, assessed by increases in L* and ITA° values, along with an increase in skin radiance and shine, were observed as early as week 2, with continued improvement through week 12 in both the treatment groups relative to baseline. At week 12, changes in radiance and shine were trending toward enhancement in the regimen group compared with the serum group.
DISCUSSION: This study demonstrates the clinical effectiveness of Thiamidol-containing formulations in the visible improvement of facial hyperpigmentation and in overall skin radiance and shine.
CONCLUSION: These data support the use of Thiamidol-containing formulations as part of the overall management strategy for individuals affected by facial hyperpigmentation.  .
PMID:41329151 | DOI:10.36849/JDD.9517
